Several studies have demonstrated that Gαh-OE correlates with metastatic progression [35–39] as well as drug resistance [40, 41] in different types of cancer, suggesting that the discovery of inhibitors of PPI in the Gαh/PLC-δ1 complex could be a novel and useful strategy to combat malignant tumors. Here, PLCD1 is linked to cancer.